Knut Engels - Publications

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

Journal: ESMO open

Published: June 18, 2025

Comparative evaluation of subtotal and total tonsillectomy in the management of chronic tonsillopharyngitis in adults.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Published: May 26, 2025

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.

Journal: NPJ breast cancer

Published: March 13, 2024

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 08, 2024

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2022

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: May 19, 2022

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.

Journal: BMC cancer

Published: June 14, 2021

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 08, 2021

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 27, 2020

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 18, 2019

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 17, 2019

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Journal: Geburtshilfe und Frauenheilkunde

Published: March 23, 2019